What's Happening?
Epigenic Therapeutics has completed a $60 million Series B financing round to accelerate the clinical development of its epigenetic medicines. The funding will support ongoing trials for treatments targeting chronic hepatitis B and hypercholesterolemia, as well as advance preclinical programs. Epigenic's proprietary technology platforms, including EPIREG and EpiTax, offer innovative approaches to gene modulation therapy, aiming to provide safer alternatives to traditional gene-editing methods.
Why It's Important?
The successful financing round underscores the growing interest in epigenetic medicine as a promising field for treating chronic diseases. Epigenic Therapeutics' innovative platforms could revolutionize gene therapy, offering precise and safe solutions for conditions like hepatitis and cardiovascular diseases. The investment highlights the potential of epigenetic approaches to address unmet medical needs, paving the way for new treatments that could improve patient outcomes and expand therapeutic options.
